Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Allogene Therapeutics (ALLO) Cash from Investing Activities: 2018-2024

Historic Cash from Investing Activities for Allogene Therapeutics (ALLO) over the last 7 years, with Dec 2024 value amounting to $75.7 million.

  • Allogene Therapeutics' Cash from Investing Activities rose 115.71% to $11.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was $116.9 million, marking a year-over-year increase of 32.49%. This contributed to the annual value of $75.7 million for FY2024, which is 53.65% down from last year.
  • According to the latest figures from FY2024, Allogene Therapeutics' Cash from Investing Activities is $75.7 million, which was down 53.65% from $163.3 million recorded in FY2023.
  • Allogene Therapeutics' Cash from Investing Activities' 5-year high stood at $163.7 million during FY2021, with a 5-year trough of -$505.1 million in FY2020.
  • For the 3-year period, Allogene Therapeutics' Cash from Investing Activities averaged around $115.0 million, with its median value being $106.2 million (2022).
  • Its Cash from Investing Activities has fluctuated over the past 5 years, first crashed by 407.84% in 2020, then spiked by 132.40% in 2021.
  • Yearly analysis of 5 years shows Allogene Therapeutics' Cash from Investing Activities stood at -$505.1 million in 2020, then spiked by 132.40% to $163.7 million in 2021, then crashed by 35.13% to $106.2 million in 2022, then spiked by 53.82% to $163.3 million in 2023, then tumbled by 53.65% to $75.7 million in 2024.